Investigators compared early oncologic outcomes by staging modality among men diagnosed with very high-risk prostate cancer.

“Given the expanding treatment options for advanced prostate cancer, especially PSMA-targeted radioligand therapy, there is an increasing need to understand treatment eligibility and response ...

BEDFORD, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find ...

Overall, PSMA-PET/CT detected distant metastasis in 84 of 182 cases (46%) that were negative by other types of imaging, including polymetastatic disease (≥5 lesions) in a quarter of patients.

A new diagnostic agent, Gallium 68 PSMA-11, has been approved for institutional use in the PET imaging of PSMA-positive lesions in men with prostate cancer.

Additionally, PSMA PET/CT was superior in spotting the dominant nodule (94% vs 83%), laterality (64% vs 44%), and extracapsular extension (75% vs 63%). All differences were also significant.

PSMA-PET scans detected metastatic disease in 46% of patients, indicating understaging by conventional imaging in high-risk nonmetastatic hormone-sensitive prostate cancer. The study involved 182 ...

The Crucial Role of PSMA PET Scans in Prostate Cancer. Previously, before the “PSMA PET era,” Andrews said, patients with prostate cancer underwent conventional imaging and received treatments that ...

PSMA PET has set the stage for development of PSMA-based radioligand therapies such as lutetium-177-PSMA-617 (177 Lu-PSMA-617) that target and kill PSMA-expressing prostate cancer cells.

Head-to-head comparison of micro-ultrasound, mpMRI, and PSMA PET/CT with a wholemount histopathology as gold standard in the detection and T staging of prostate cancer.. JCO 43 , 338-338 (2025). DOI: ...